ImClone Systems said Thursday that its cancer drug Erbitux did not help stave off the disease in patients with metastatic lung cancer, sending the company's shares down 6% in premarket trading.
The trial of roughly 600 patients tested Erbitux in combination with chemotherapy, in patients with lung cancer who had not received prior treatment.
Results of a bigger late-stage trial of the drug, which is currently approved to treat colon cancer and head and neck cancer, are not yet available.
The bigger trial, which is testing the drug with a different chemotherapy regime, would form the basis of a marketing application with regulators.
ImClone markets Erbitux with partner Bristol-Myers Squibb . Shares in ImClone fell 8.1% in pre-market trading.